Sanofi’s Keeney On Early-Stage Assets, 'Open Dialogue' With Asian Start-Ups
Executive Summary
Dr. Adam Keeney, Global Head, External Innovation and R&D Strategy at Sanofi, outlines in an interview with Scrip the company’s interest in early-stage assets and intent to tap into opportunities in Asia-Pacific. He also discusses the region’s role as a digital hub.
You may also be interested in...
China's Harbour BioMed Mulls Global Licensing
The Shanghai-based biotech startup Harbour Biomed hopes overseas licensing will propel it towards an initial offering in the US, following in the footsteps of a successful approach pioneered by BeiGene.
How Sanofi Is Stepping Up Blue Sky Research With Academia
French multinational Sanofi is keen to take global its
Momentum At Indian Innovation Start-Ups: Will Pharma Take Notice?
Several Indian startups - many with overseas links - appear to be taking a shot at developing, among others, novel treatments targeting multi-drug resistant infections, biobetters and personalized cell based therapy. Funding, though, hasn’t been easy, according to one biopharma advisory firm.